Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection.
Vaccine
; 39(36): 5205-5213, 2021 08 23.
Article
em En
| MEDLINE
| ID: mdl-34362603
ABSTRACT
Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in hospitalization or death. In this study, TLR4 immunostimulatory molecules, Bacterial Enzymatic Combinatorial Chemistry (BECC) 438 and BECC470 were found to be superior IAV vaccine adjuvants when compared to the classic adjuvant alhydrogel (alum) and Phosphorylated Hexa-Acyl Disaccharide (PHAD), a synthetic TLR4 agonist. BECC molecules allow for antigen sparing of a recombinant HA (rHA) protein, elicit a more balanced IgG1/IgG2a response, and were protective in a prime only dosing schedule. Importantly, BECC molecules afford protection from a heterologous IAV strain demonstrating that a cross-protective influenza vaccine is possible when the antigen is effectively adjuvanted.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra Influenza
/
Infecções por Orthomyxoviridae
/
Influenza Humana
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article